Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Role of genetic background in the effects of adolescent nicotine exposure on mesolimbic dopamine transmission.

Cadoni C, De Felice M, Corongiu S, Dessì C, Espa E, Melis M, Fenu S.

Addict Biol. 2019 Jul 24:e12803. doi: 10.1111/adb.12803. [Epub ahead of print]

PMID:
31342609
2.

Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.

Boi L, Pisanu A, Greig NH, Scerba MT, Tweedie D, Mulas G, Fenu S, Carboni E, Spiga S, Carta AR.

Mov Disord. 2019 Dec;34(12):1818-1830. doi: 10.1002/mds.27799. Epub 2019 Jul 23.

PMID:
31335998
3.

Saposin B deficiency as a cause of adult-onset metachromatic leukodystrophy.

Fenu S, Castellotti B, Farina L, Cavallaro T, Di Bella D, Benzoni C, Gellera C, Pareyson D, Taroni F, Salsano E.

Neurology. 2019 Aug 13;93(7):310-312. doi: 10.1212/WNL.0000000000007951. Epub 2019 Jul 9. No abstract available.

PMID:
31289144
4.

Neuropsychological features of adult form of Alexander disease.

Draghi L, Salsano E, Farina L, Di Bella D, Fenu S, Pareyson D, Taroni F, Piacentini SHMJ.

J Neurol Sci. 2019 Jun 15;401:87-89. doi: 10.1016/j.jns.2019.04.030. Epub 2019 Apr 23. No abstract available.

PMID:
31039531
5.

Spastic paraplegia due to SPAST mutations is modified by the underlying mutation and sex.

Parodi L, Fenu S, Barbier M, Banneau G, Duyckaerts C, Tezenas du Montcel S, Monin ML, Ait Said S, Guegan J, Tallaksen CME, Sablonniere B, Brice A, Stevanin G, Depienne C, Durr A; SPATAX network.

Brain. 2018 Dec 1;141(12):3331-3342. doi: 10.1093/brain/awy285.

PMID:
30476002
6.

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT.

Br J Haematol. 2019 Jun;185(5):954-957. doi: 10.1111/bjh.15655. Epub 2018 Nov 8. No abstract available.

PMID:
30407614
7.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS).

Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. No abstract available.

PMID:
30029156
8.

Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Pisanu A, Boi L, Mulas G, Spiga S, Fenu S, Carta AR.

J Neural Transm (Vienna). 2018 Aug;125(8):1287-1297. doi: 10.1007/s00702-018-1874-4. Epub 2018 Mar 14. Review.

PMID:
29541852
9.

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

Mayer F, Faglioni L, Agabiti N, Fenu S, Buccisano F, Latagliata R, Ricci R, Spiriti MAA, Tatarelli C, Breccia M, Cimino G, Fianchi L, Criscuolo M, Gumenyuk S, Mancini S, Maurillo L, Nobile C, Niscola P, Piccioni AL, Tafuri A, Trapè G, Andriani A, De Fabritiis P, Voso MT, Davoli M, Zini G.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017046. doi: 10.4084/MJHID.2017.046. eCollection 2017.

10.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

11.

Hereditary spastic paraplegia: More than an upper motor neuron disease.

Parodi L, Fenu S, Stevanin G, Durr A.

Rev Neurol (Paris). 2017 May;173(5):352-360. doi: 10.1016/j.neurol.2017.03.034. Epub 2017 Apr 24. Review.

PMID:
28449883
12.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

PMID:
28419408
13.

Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.

Mulas G, Espa E, Fenu S, Spiga S, Cossu G, Pillai E, Carboni E, Simbula G, Jadžić D, Angius F, Spolitu S, Batetta B, Lecca D, Giuffrida A, Carta AR.

Exp Neurol. 2016 Dec;286:83-92. doi: 10.1016/j.expneurol.2016.09.013. Epub 2016 Sep 30.

PMID:
27697481
14.

In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.

Fenu S, Espa E, Pisanu A, Di Chiara G.

Eur J Pharmacol. 2016 Oct 5;788:183-191. doi: 10.1016/j.ejphar.2016.06.035. Epub 2016 Jun 22.

PMID:
27343381
15.

Role of nucleus accumbens μ opioid receptors in the effects of morphine on ERK1/2 phosphorylation.

Rosas M, Porru S, Fenu S, Ruiu S, Peana AT, Papale A, Brambilla R, Di Chiara G, Acquas E.

Psychopharmacology (Berl). 2016 Aug;233(15-16):2943-54. doi: 10.1007/s00213-016-4340-8. Epub 2016 May 31.

PMID:
27245230
16.

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L, Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R; GROM (Gruppo Romano Mielodisplasie).

Ann Hematol. 2016 Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19.

PMID:
27091349
17.

Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F.

Leuk Res. 2015 Aug;39(8):859-65. doi: 10.1016/j.leukres.2015.05.012. Epub 2015 Jun 12.

PMID:
26120100
18.

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.

Voso MT, Niscola P, Piciocchi A, Fianchi L, Maurillo L, Musto P, Pagano L, Mansueto G, Criscuolo M, Aloe-Spiriti MA, Buccisano F, Venditti A, Tendas A, Piccioni AL, Zini G, Latagliata R, Filardi N, Fragasso A, Fenu S, Breccia M; GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry.

Eur J Haematol. 2016 Apr;96(4):344-51. doi: 10.1111/ejh.12595. Epub 2015 Jun 21.

PMID:
26018238
19.

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.

Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.

Eur J Haematol. 2015 Jul;95(1):52-6. doi: 10.1111/ejh.12476. Epub 2015 Mar 12.

PMID:
25764148
20.

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.

Breccia M, Voso MT, Aloe Spiriti MA, Fenu S, Maurillo L, Buccisano F, Tafuri A, Alimena G.

Ann Hematol. 2015 May;94(5):771-7. doi: 10.1007/s00277-015-2341-z. Epub 2015 Mar 7. Review.

PMID:
25743685
21.

Prospective study of hepatitis B virus reactivation in patients with hematological malignancies.

Pompili M, Basso M, Hohaus S, Bosco G, Nosotti L, D'Andrea M, Fenu S, Grieco A, Laurenti L, Mirisola C, Pagano L, Rapaccini GL, Sica S, Storti S, Landolfi R.

Ann Hepatol. 2015 Mar-Apr;14(2):168-74.

22.

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.

Fianchi L, Pagano L, Piciocchi A, Candoni A, Gaidano G, Breccia M, Criscuolo M, Specchia G, Maria Pogliani E, Maurillo L, Aloe-Spiriti MA, Mecucci C, Niscola P, Rossetti E, Mansueto G, Rondoni M, Fozza C, Invernizzi R, Spadea A, Fenu S, Buda G, Gobbi M, Fabiani E, Sica S, Hohaus S, Leone G, Voso MT.

Am J Hematol. 2015 May;90(5):E80-5. doi: 10.1002/ajh.23966. Epub 2015 Mar 3.

23.

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.

Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F.

Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub 2014 Oct 1.

PMID:
25272332
24.

NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.

Reghellin V, Donnici L, Fenu S, Berno V, Calabrese V, Pagani M, Abrignani S, Peri F, De Francesco R, Neddermann P.

Antimicrob Agents Chemother. 2014 Dec;58(12):7128-40. doi: 10.1128/AAC.03293-14. Epub 2014 Sep 15.

25.

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.

Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E.

BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9.

PMID:
25204541
26.

In vitro antibiofilm activity of bioactive glass S53P4.

Drago L, Vassena C, Fenu S, De Vecchi E, Signori V, De Francesco R, Romanò CL.

Future Microbiol. 2014;9(5):593-601. doi: 10.2217/fmb.14.20.

PMID:
24957087
27.

Photodynamic antibacterial and antibiofilm activity of RLP068/Cl against Staphylococcus aureus and Pseudomonas aeruginosa forming biofilms on prosthetic material.

Vassena C, Fenu S, Giuliani F, Fantetti L, Roncucci G, Simonutti G, Romanò CL, De Francesco R, Drago L.

Int J Antimicrob Agents. 2014 Jul;44(1):47-55. doi: 10.1016/j.ijantimicag.2014.03.012. Epub 2014 May 21.

PMID:
24933446
28.

Acquisition and expression of conditioned taste aversion differentially affects extracellular signal regulated kinase and glutamate receptor phosphorylation in rat prefrontal cortex and nucleus accumbens.

Marotta R, Fenu S, Scheggi S, Vinci S, Rosas M, Falqui A, Gambarana C, De Montis MG, Acquas E.

Front Behav Neurosci. 2014 May 7;8:153. doi: 10.3389/fnbeh.2014.00153. eCollection 2014.

29.

Conditioned saccharin avoidance induced by infusion of amphetamine in the nucleus accumbens shell and morphine in the ventral tegmental area: behavioral and biochemical study.

Fenu S, Espa E, Cadoni C, Di Chiara G.

Behav Brain Res. 2014 Aug 1;269:55-60. doi: 10.1016/j.bbr.2014.03.049. Epub 2014 Apr 26.

PMID:
24780866
30.

Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.

Tatarelli C, Piccioni AL, Maurillo L, Naso V, Battistini R, D'Andrea M, Criscuolo M, Nobile C, Villivà N, Mancini S, Neri B, Breccia M, Fenu S, Buccisano F, Voso MT, Latagliata R, Aloe Spiriti MA.

Ann Hematol. 2014 Aug;93(8):1413-20. doi: 10.1007/s00277-014-2053-9. Epub 2014 Mar 20.

PMID:
24647684
31.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
32.

Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.

Breccia M, Voso MT, Maurillo L, Niscola P, Fianchi L, Aloe Spiriti MA, Buccisano F, Latagliata R, Pelliccia S, Fenu S, Tendas A, Alimena G.

Am J Hematol. 2014 May;89(5):565. doi: 10.1002/ajh.23677. Epub 2014 Feb 28. No abstract available.

33.

Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.

Ottone T, Hasan SK, Voso MT, Ledda A, Montefusco E, Fenu S, Pagoni M, Hubmann M, Lunghi M, Platzbecker U, Lo-Coco F.

Am J Hematol. 2014 Mar;89(3):346-7. doi: 10.1002/ajh.23646. No abstract available.

34.

Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats.

Cadoni C, Simola N, Espa E, Fenu S, Di Chiara G.

Addict Biol. 2015 Jan;20(1):132-42. doi: 10.1111/adb.12085. Epub 2013 Aug 20.

PMID:
23957273
35.

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.

Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D'Andrea M, D'Addosio A, Leone G, Venditti A.

J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24.

PMID:
23796988
36.

Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward.

Simola N, Fenu S, Costa G, Pinna A, Plumitallo A, Morelli M.

Neuropharmacology. 2012 Aug;63(2):224-34. doi: 10.1016/j.neuropharm.2012.03.013. Epub 2012 Mar 23.

PMID:
22465816
37.

Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.

Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, Abrignani S, Neddermann P, De Francesco R.

PLoS Pathog. 2012;8(3):e1002576. doi: 10.1371/journal.ppat.1002576. Epub 2012 Mar 8.

38.

Behavioral and neurochemical pharmacology of 5-HT6 receptors related to reward and reinforcement.

Di Chiara G, Valentini V, Fenu S.

Int Rev Neurobiol. 2011;96:111-39. doi: 10.1016/B978-0-12-385902-0.00005-X. Review. No abstract available.

PMID:
21329786
39.

From c-Photina mouse embryonic stem cells to high-throughput screening of differentiated neural cells via an intermediate step enriched in neural precursor cells.

Cainarca S, Fenu S, Bovolenta S, Arioli P, Menegon A, Lohmer S, Corazza S.

J Biomol Screen. 2010 Oct;15(9):1132-43. doi: 10.1177/1087057110379267. Epub 2010 Sep 10.

PMID:
20834010
40.

Pharmacological therapy of Parkinson's disease: current options and new avenues.

Simola N, Pinna A, Fenu S.

Recent Pat CNS Drug Discov. 2010 Nov;5(3):221-38. Review.

PMID:
20726838
41.

Conditioned saccharin avoidance and sensitization to drugs of abuse.

Fenu S, Cadoni C, Di Chiara G.

Behav Brain Res. 2010 Dec 25;214(2):248-53. doi: 10.1016/j.bbr.2010.05.044. Epub 2010 May 31.

PMID:
20561960
42.

A photoprotein in mouse embryonic stem cells measures Ca2+ mobilization in cells and in animals.

Cainarca S, Fenu S, Ferri C, Nucci C, Arioli P, Menegon A, Piemonti L, Lohmer S, Wrabetz L, Corazza S.

PLoS One. 2010 Jan 27;5(1):e8882. doi: 10.1371/journal.pone.0008882.

43.

Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease.

Fenu S, Wardas J, Morelli M.

Behav Pharmacol. 2009 Sep;20(5-6):363-79. doi: 10.1097/FBP.0b013e32833109a0. Review.

PMID:
19724195
44.

Fibrillar collagen inhibits cholesterol biosynthesis in human aortic smooth muscle cells.

Ferri N, Roncalli E, Arnaboldi L, Fenu S, Andrukhova O, Aharinejad S, Camera M, Tremoli E, Corsini A.

Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1631-7. doi: 10.1161/ATVBAHA.109.187807. Epub 2009 Jul 16.

45.

Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?

Veltroni M, Sainati L, Zecca M, Fenu S, Tridello G, Testi AM, Merlone AD, Buldini B, Leszl A, Lo Nigro L, Longoni D, Bernini G, Basso G; AIEOP-MDS Study Group.

Pediatr Blood Cancer. 2009 Mar;52(3):357-63. doi: 10.1002/pbc.21874.

PMID:
19061215
46.

Differential involvement of dopamine D1 receptors in morphine- and lithium-conditioned saccharin avoidance.

Fenu S, Rivas E, Di Chiara G.

Physiol Behav. 2009 Jan 8;96(1):73-7. doi: 10.1016/j.physbeh.2008.08.017. Epub 2008 Aug 28.

PMID:
18790704
47.
48.

Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.

Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C.

Cancer Res. 2006 Sep 1;66(17):8903-11.

49.

Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.

Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M.

Exp Neurol. 2006 Nov;202(1):255-7. Epub 2006 Jun 30.

PMID:
16808917
50.

Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.

Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M.

J Neurol Sci. 2006 Oct 25;248(1-2):48-52. Epub 2006 Jun 15.

PMID:
16780890

Supplemental Content

Support Center